Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Companies
Patients
Investigators
Trials & Research
Regulatory
Therapeutics
News
Features
Commentary
People
Events
White Papers
Home
HEADLINE NEWS
PPD and VirtualScopics expand strategic alliance for medical imaging services
27 January 2012
PPD and VirtualScopics have expanded their one-year strategic alliance in clinical and medical imaging services across multiple therapeutic areas to now include oncology, central nervous system, cardiovascular, general medicine and medical devices. The companies deliver integrated and customised ...
Ergomed partners Hikma for oncology trials in Jordan
26 January 2012
Hikma Pharmaceuticals is to partner with the German full-service CRO Ergomed , which will manage clinical trials of Hikma oncology treatments in a pilot project in Jordan. Ergomed will be conducting the first clinical trials for one of Hikma’s key oncology products in Jordanian hospitals, with ...
Parexel extends early-phase network with UK hospital collaboration
24 January 2012
Parexel International has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom, to expand its early-phase alliance network. The CRO's alliance ...
Lilly exit from JV with Jubilant doesn't end commitment to FIPNet strategy
24 January 2012
Lilly and the Jubilant group have exited their equally owned Indian joint venture for early stage drug development, Vanthys, though the US multinational suggests that the decision is in no way indicative of any departure from its fully integrated pharmaceutical network strategic approach to capture ...
>> More Headline News...
NEWS
PPD and VirtualScopics expand strategic alliance for medical imaging services
27 January 2012
PPD and VirtualScopics have expanded their one-year strategic alliance in clinical and medical imaging services across multiple therapeutic areas to now include oncology, central nervous system, cardiovascular, general medicine and medical devices. The companies deliver integrated and customised ...
Ergomed partners Hikma for oncology trials in Jordan
26 January 2012
Hikma Pharmaceuticals is to partner with the German full-service CRO Ergomed , which will manage clinical trials of Hikma oncology treatments in a pilot project in Jordan. Ergomed will be conducting the first clinical trials for one of Hikma’s key oncology products in Jordanian hospitals, with ...
Parexel extends early-phase network with UK hospital collaboration
24 January 2012
Parexel International has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom, to expand its early-phase alliance network. The CRO's alliance ...
Lilly exit from JV with Jubilant doesn't end commitment to FIPNet strategy
24 January 2012
Lilly and the Jubilant group have exited their equally owned Indian joint venture for early stage drug development, Vanthys, though the US multinational suggests that the decision is in no way indicative of any departure from its fully integrated pharmaceutical network strategic approach to capture ...
Quintiles invests in biomarker start-up; Glyn Edwards to head
20 January 2012
Quintiles has invested £3 million in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomarkers to clients. Glyn Edwards , the ex-CEO of Antisoma and the interim CEO of the BioIndustry ...
>> More News...
FEATURES
Improved climate for clinical trials in Thailand
26 January 2012
Incoming Thai Prime Minister Yingluck Shinawatra gained much support from the local pharma community last year on announcing a series of health policy goals. She won the mandate to reform the healthcare and other sectors of the Thai economy after her PTP party’s landslide victory in the July 2011 ...
Strategies for controlling clinical study costs
05 January 2012
Clinical study design teams have historically been cost conscious, but not necessarily cost averse. The cost conscious clinical team will forecast study costs and have a keen awareness that choices made in study design will have monetary consequences for the study budget. The cost averse clinical ...
Compliance issues beset hypertension market
24 November 2011
On the face of it, one would think that patients prescribed antihypertensive medication would be happy to take it. After all, the benefits of treating asymptomatic hypertension – specifically, a reduced risk of heart attack and stroke – are well established. But studies have repeatedly shown that ...
The red, white, blue and grey of Russian trials
24 November 2011
The Russian law on circulation of medicines, which came into effect in September 2010, brought some clarification to the clinical trial approvals framework, but also a great deal of uncertainty and confusion. One year on, the situation has stabilised in a number of respects, but some grey areas ...
>> More Features...
PEOPLE
ICON strengthens Global Scientific Council
ICON has appointed Professor Brendan Buckley and Dr Nicholas Alp to the company’s Global Scientific Council. Professor Buckley has been appointed senior vice-president, medical affairs, having joined ICON in July 2011 through the company’s acquisition of Firecrest Clinical. Dr Alp has been ...
Premier Research names Drouet as European exec director of oncology
Premier Research has hired Etienne Drouet as its new executive director of oncology in Europe. In this position, Drouet will play a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology business. Drouet has more than 19 ...
Ex-FDA director joins Parexel
Parexel Consulting , a business unit of Parexel International, has hired David Elder , formerly a senior official of the US FDA, as vice-president of its Strategic Compliance Services team. At the FDA, Elder served as the director of the Office of Regional Operations (ORO) within the Office of ...
>> More People...
COMMENTARY
Deals to drive innovation for the next three billion
Deals such as ICON’s recent acquisition of BeijingWits Medical Consulting not only reflect the opportunity presented by emerging growth markets but also the need for local knowledge to conduct business effectively and tailor new product development to local market needs. We expect more deals to ...
Prepare for the regulatory revolution
Every medicine has associated side effects, or adverse drug reactions (ADRs). The European Impact Assessment Report on Pharmacovigilance (PV) estimated that approximately 5% of all hospital admissions are due to ADRs and that ADRs are the fifth most common cause of hospital death, accounting for an ...
CROs: focus on therapeutic areas for project gains
Lifestyle, living standards and longevity will all play their part in the disease profile of the future global population. Aligned with these factors is the shifting market for pharmaceuticals, an increasing proportion of profits will come from outside of the US and Europe as the developing world ...
Navigating the sea of data protection law in European clinical research
In Europe, there is a common set of rules that regulate the collection, use, and sharing of personal data. These include strict protection of sensitive data such as health data. However, individual European countries have interpreted and implemented the rules on the use of health data in clinical ...
Lean strategies for R&D partnership transformation
Lean methods for transformation, believes Deloitte 's Julian Remnant , could form a foundation for multi-company collaborations that might define the next generation of industry partnerships. In my April column, I recognised the benefits R&D organisations have realised from the first generation of ...
Delivery partners will have opportunity to shape sponsor IT strategy
Information technology investments in R&D will begin to target the ‘value analytics’ agenda, believes Deloitte 's Julian Remnant , and to do so, he suggests sponsors will increasingly draw on their delivery partners to shape operational IT strategy. The last ten years has seen industry-wide IT ...
>> More Commentary...
About Us
Getting Started
Subscribe
FREE Trial
Advertise
Awards
White Papers
EVENTS
Partnerships in Clinical Trials
04 March 2012
The Marriott World Center, Orlando, Florida
